Related Experiment Video
Updated: Jan 6, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Mepolizumab reduced healthcare resource utilization and improved work productivity in patients with severe asthma
Giorgio Walter Canonica1,2, Arnaud Bourdin3, Erika Penz4
1Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Objective:
To assess the real-world impact of mepolizumab on healthcare resource utilization (HCRU) and work productivity and activity impairment (WPAI) in patients with severe asthma.
Methods:
Asthma-related HCRU and WPAI were assessed over 2 years in the REALITI-A study-an international, prospective, observational cohort study in adults with severe asthma newly initiating mepolizumab (100 mg subcutaneous). Secondary endpoints of the study compared the proportion of patients with HCRU use, HCRU events, and WPAI component scores 12 months before mepolizumab initiation with 24 months follow-up. The relative rates of HCRU outcomes were calculated, with a treatment policy estimand for discontinuation.
Results:
Patients (N = 822) had a mean age of 54 years and 63% were female. Hospitalization rates were reduced by 53% in the 0-12-month follow-up period (p < 0.001) and sustained for 24 months. The rates of asthma-related hospitalizations, emergency department visits, and outpatient visits reduced by 59-64% (p < 0.001) across the 24-month follow-up. The mean number of overnight hospital stays reduced from 2.4 in the pre-treatment period to 1.0 and 0.5 in the 0-12-month and 12-24-month follow-up periods, respectively. The WPAI Asthma activity impairment score was reduced from baseline by 47% and 55% at 12 and 24 months of follow-up. Overall work impairment was reduced by 62% and 74%.
Conclusions:
Mepolizumab treatment reduced HCRU while improving activity and productivity in patients with severe asthma over 2 years. These data provide further evidence of real-world benefits of mepolizumab and may help inform healthcare system resource allocation.
More Related Videos
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
09:58A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...